EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
ConditionHER2 Positive Early Breast Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorFudan University
About this trial
compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients
Eligibility criteria
Qualifiers
Women aged 18-70；
0-1 for ECOG；
Unilateral invasive carcinoma confirmed by histology (regardless of pathological type)；
No gross or microscopic tumor remains after surgical resection；
Disqualifiers
Bilateral breast cancer or carcinoma in situ DCIS/LCIS；
Have received chemotherapy for advanced disease；
Transfer of any part；
If any tumor >T4a (accompanied by skin invasion, mass adhesion fixation, inflammatory breast cancer)；
Trial design
Treatments tested in this trial
- Docetaxel
- carboplatin
- Trastuzumab
- Pertuzumab
- Epirubicin
- cyclophosphamide
Treatment groups
1,406 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov